An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies.
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2010
At a glance
- Drugs Alemtuzumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CARE-MS-I; CARE-MS-II
- 10 Jun 2017 Biomarkers information updated
- 14 Oct 2010 Pooled demographic and baseline disease characteristics of patients enrolled in the CARE-MS-I trial were presented in an abstract at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 25 Dec 2009 New trial record